title: Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus.
abstract: OBJECTIVE
  The atherogenicity of chylomicron remnants has been discussed. We examined whether serum apoB48 level is associated with the presence of carotid plaque in type 2 diabetic patients.
  
  
  METHODS
  Forty type 2 diabetic patients (21 males and 19 females, 52.8+/-11.8 years old; mean+/-S.D.) were divided into two groups by the presence or absence of carotid plaque. The diurnal change of serum apoB48 level was measured by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Fasting serum apoB48 level was higher in the subjects with carotid plaque than those without (6.5+/-3.8vs. 4.1+/-1.9 microg/ml, p=0.01). Age- and gender-adjusted analysis showed that the presence of carotid plaque was associated with fasting apoB48 (OR 1.43; 95% CI, 1.07-2.09, p=0.04) and triglyceride (OR 1.14; 95% CI, 1.02-1.32, p=0.04) levels. In normal LDL-cholesterol (<140 mg/dl) subjects, the presence of carotid plaque was associated with fasting apoB48 level (OR 2.16; 95% CI, 1.22-5.32, p=0.04), but not associated with fasting triglyceride level (OR 1.11; 95% CI, 0.99-1.30, p=0.13).
  
  
  CONCLUSIONS
  Serum apoB48 level was strongly associated with the presence of carotid plaque in type 2 diabetic patients.
authors.affiliation: Department of Medicine, Division of Endocrinology and Metabolism, Nippon Medical School, Tokyo, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Tanimura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Mototugu
authors.initials: M
authors.lastname: Nagao
authors.forename: Akira
authors.initials: A
authors.lastname: Ishizaki
authors.forename: Toshiko
authors.initials: T
authors.lastname: Kano
authors.forename: Taro
authors.initials: T
authors.lastname: Harada
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Okajima
authors.forename: Mariko
authors.initials: M
authors.lastname: Sudo
authors.forename: Hideki
authors.initials: H
authors.lastname: Tamura
authors.forename: Shinya
authors.initials: S
authors.lastname: Ishii
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sugihara
authors.forename: Shizuya
authors.initials: S
authors.lastname: Yamashita
authors.forename: Akira
authors.initials: A
authors.lastname: Asai
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oikawa
mesh_terms: D000328:Adult; D000368:Aged; D053283:Apolipoprotein B-48 / Q000097:blood*; D001794:Blood Pressure; D016893:Carotid Stenosis / Q000097:blood* / Q000503:physiopathology; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000097:blood* / Q000503:physiopathology; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D053283:Apolipoprotein B-48; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D014280:Triglycerides